This volume is devoted to descriptions of non medical as well as medical uses for some drugs that have typically, or not so typically, been associated with drug abuse. One major objective of this book is to identify costs and benefits of drug abuse. The book highlights drugs including 3,4 methylenedioxymethamphetamine (MDMA), cannabinoids, opioids and methylphenidate because of their well-documented potential for abuse and provides new and emerging evidence of their potential to treat some chronic disease states alongside the potential consequences of exposure.
Edited by:
Suzanne Nielsen,
Raimondo Bruno,
Susan Schenk
Imprint: Springer International Publishing AG
Country of Publication: Switzerland
Edition: 2017 ed.
Volume: 34
Dimensions:
Height: 235mm,
Width: 155mm,
Weight: 4.439kg
ISBN: 9783319600147
ISBN 10: 3319600141
Series: Current Topics in Behavioral Neurosciences
Pages: 198
Publication Date: 23 August 2017
Audience:
Professional and scholarly
,
Undergraduate
Format: Hardback
Publisher's Status: Active
Preface.- Preclinical effects of antipsychotic drugs.- Contribution of Impulsivity and Serotonin Receptor Neuroadaptations to the development of an MDMA (“ecstasy”) Substance Use Disorder.- The Abuse Potential of Prescription Opioids in Humans – Closing in on the First Century of Research.- Over-the-Counter codeine –from therapeutic use to dependence, and the grey areas in between.- Injection of pharmaceuticals designed for oral use: Harms experienced and effective harm reduction through filtration.- Misuse of Methylphenidate.- Misuse and Associated Harms of Quetiapine, and Other Atypical Antipsychotics.- Benzodiazepines.- Recent trends in alcohol and other drug use among police detainees in New Zealand, 2010–2015.- The Impact of Legalizing and Regulating Weed: Issues with Study Design and Emerging Findings in the U.S.
